Lipid Lowering Treatment and Eligibility for PCSK9 Inhibition in Post-Myocardial Infarction Patients in Italy: Insights from Two Contemporary Nationwide Registries

Table 2

Pharmacological therapy at discharge/end visit according to baseline LDL-C levels.

	Total (n. 3074)	LDL-C < 70 mg/dl (n. 1186)	LDL-C 70–99 mg/dl (n. 1150)	LDL-C ≥ 100 mg/dl (n. 738)
Oral anticoagulants, (%)	288 (9.4)	110 (9.3)	98 (8.5)	80 (10.8)	0.24
ASA, (%)	2785 (90.6)	1086 (91.6)	1050 (91.3)	649 (87.9)	0.02
Thienopyridine, ^§ (%)	1597 (52.0)	614 (51.8)	556 (48.4)	427 (57.9)	0.0003
ASA/thienopyridine, (%)	2946 (95.8)	1140 (96.1)	1103 (95.9)	703 (95.3)	0.64
DAPT (ASA + thienopyridine), (%)	1436 (46.7)	560 (47.2)	503 (43.7)	373 (50.5)	0.01
ACE-inhibitors, (%)	1735 (56.4)	694 (58.5)	635 (55.2)	406 (55.0)	0.18
ARBs, (%)	690 (22.5)	269 (22.7)	274 (23.8)	147 (19.9)	0.14
ACE/ARBs	2405 (78.2)	958 (80.8)	902 (78.4)	545 (73.9)	0.002
Beta-blockers, (%)	2457 (79.9)	976 (82.3)	914 (79.5)	567 (76.8)	0.01
Mineralcorticoid antagonists (MRAs), (%)	334 (10.9)	138 (11.6)	123 (10.7)	73 (9.9)	0.48
Statins, (%)	2928 (95.3)	1152 (97.1)	1106 (96.2)	670 (90.8)	<0.0001
Low-dose statins	286 (9.3)	105 (8.9)	130 (11.3)	51 (6.9)	0.005
High-intensity statins	1888 (61.4)	753 (63.5)	690 (60.0)	445 (60.3)	0.17
Dose of statins (mg), mean SD)
Atorvastatin	40 [40-40]	40 [20–40]	40 [40-40]	40 [40–80]	0.0009
Fluvastatin	80 [80-80]	—	45 [10–80]	80 [80-80]	0.41
Lovastatin	20 [20–40]	30 [20–40]	20 [20–40]	40 [20–40]	0.66
Pravastatin	40 [40-40]	40 [40-40]	40 [40-40]	40 [40-40]	0.73
Rosuvastatin	15 [10–20]	10 [10–20]	20 [10–20]	20 [10–20]	0.09
Simvastatin	20 [20–40]	20 [20–40]	20 [20–40]	40 [20–40]	0.02

ASA, aspirin; DAPT, dual antiplatelet therapy, ACE angiotensin converting enzyme; ARB, angiotensin receptor blockers.^§Clopidogrei/prasugrel/ticagrelor/ticlopidina.